FLNA:BMV
Filana Therapeutics Inc
MX$15.92
0.00%
(0.00) 1 دن
5 اکتوبر, 12:05:31 PM GMT -6 · MXN
search
تمام علامات
| علامت | قیمت | تبدیلی | % تبدیلی |
|---|
insights_autoFLNA کے لیے سرفہرست بصیرتیں تخلیق کی جا رہی ہیں...
مارکیٹ کی سرمایہ کاری
3.49 کروڑ
اوسط والیوم
0.00
والیوم
0.00
52 ہفتے میں اعلی
MX$56.00
52 ہفتے کا کم
MX$15.92
ملازمین کی تعداد
19
مارکیٹ کی سرمایہ کاری
3.49 کروڑ
اوسط والیوم
0.00
والیوم
0.00
52 ہفتے میں اعلی
MX$56.00
52 ہفتے کا کم
MX$15.92
ملازمین کی تعداد
19
خبریں اور کہانیاں
ویب ذرائع اور خبروں کے پارٹنرز سے
Kalkine Media
·
47 منٹ پہلے
TC Energy (NYSE:TRP): What Is Driving the NYSE Composite Story?
TradingView
·
28 منٹ پہلے
These S&P 500 stocks lead in capital efficiency - BofA
Yahoo Finance
·
31 منٹ پہلے
Winners And Losers Of Q2: Remitly (NASDAQ:RELY) Vs The Rest Of The Financial Technology Stocks
پروفائل
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. Currently led by President and CEO Richard Barry, Filana is working on developing simufilam to treat tuberous sclerosis complex–related epilepsy. The company previously was developing simufilam as an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
In June 2024, the United States Department of Justice charged an advisor to Cassava Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. Wikipedia
Filana Therapeutics Inc کے بارے میں